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Vitamin D deficiency is present in the vast majority of
patients with chronic kidney disease (CKD), and correcting
a poor vitamin D status is recommended as a treatment
of CKD–mineral and bone disorders. In this review,
we summarize the molecular and clinical data on the role
of vitamin D status for heart diseases and its risk factors,
with particular attention to patients with CKD. Experimental
studies strongly suggest that vitamin D metabolism has
a crucial role in myocardial and vascular pathophysiology.
This is supported by observations of vitamin D receptor
knockout mice, which suffer from myocardial hypertrophy
and arterial hypertension with increased activity of the
renin–angiotensin system. In the general population and
in particular in CKD patients, a poor vitamin D status is
associated with cardiovascular (CV) risk factors and preclinical
manifestations of CV disease including coronary calcification.
Poor vitamin D status is also associated with prevalent and
incident CV diseases, such as heart failure and sudden cardiac
death. Native as well as active vitamin D treatments improve
CV risk profiles and exert beneficial effects on parameters
of myocardial structure and function. Whether vitamin D
therapy is effective for the prevention or treatment of
CV disease remains to be proven in large-scale randomized
controlled trials. Native vitamin D should, however, be
supplemented in virtually all CKD patients with reduced
25-hydroxyvitamin D concentrations, and the promising
data on antiproteinuric and cardioprotective effects of
paricalcitol may extend the future indication spectrum
for active vitamin D treatment.
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Vitamin D is historically known as a major regulator of
bone and mineral metabolism.1,2 Vitamin D receptor (VDR)
expression is, however, found in almost all human tissues.1,2
It is therefore increasingly recognized that beyond chronic
kidney disease–mineral and bone disorders, vitamin D may
also have a role in cardiovascular (CV), autoimmune, and
infectious diseases, as well as in cancer.1–6 Importantly,
reduced 25-hydroxyvitamin D (25D) levels, which are used to
assess vitamin D status, have been largely associated with
increased all-cause and CV mortality in CKD patients.7–13
In light of this, it is of particular concern that the vast
majority of CKD patients have 25D below target ranges
of X30 ng/ml (75 nmol/l).14–16 This high prevalence of
vitamin D deficiency in CKD can be mainly attributed to
limited sunlight exposure, but also to impaired vitamin D
synthesis in the skin, as well as disturbances of vitamin D
metabolism, including increased loss of vitamin D metabo-
lites in the urine.15 Furthermore, reduced renal secretion of
1,25-dihydroxyvitamin D (1,25D; calcitriol), which circulates
in lower concentrations but has a higher affinity to the VDR
compared with 25D, is also common in CKD patients.15,17
Hence, CKD patients are prone to low serum levels of 25D,
which can be increased by native vitamin D supplementation,
as well as 1,25D, which can be treated by active vitamin D
supplementation with 1,25D or less calcemic VDR activa-
tors (for example, paricalcitol).18,19 According to a widely
accepted hypothesis, the local conversion of 25D to 1,25D
seems to determine tissue levels of 1,25D in various organs
with significant activities of the enzyme 1a-hydroxylase.20
Expression of both VDR and 1a-hydroxylase, in the myo-
cardium as well as in the vessel wall, suggest an involvement
of vitamin D metabolism in the pathophysiology of CV
disease.2,21 In this brief review, we summarize the current
knowledge on the role of vitamin D in CKD for myocardial
structure and function, as well as for CV diseases and its risk
factors. Finally, we discuss treatment approaches for a poor
vitamin D status.
EFFECTS OF VITAMIN D ON THE HEART
VDR and 1a-hydroxylase knockout mice with normalized
calcium levels display a cardiac phenotype characterized
by myocardial hypertrophy, increased contractility, and
impaired systolic function.2,22–26 These abnormalities can be
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reversed by blocking the renin–angiotensin–aldosterone system.
This suggests that increased renin–angiotensin–aldosterone
system activation is mainly responsible for myocardial damage
in these knockout models. In line with this, Li et al.23,27
demonstrated that 1,25D is a negative regulator of renin and
clarified molecular pathways for this effect.23,27 Although this
implies systemic effects, interestingly, cardiomyocyte-specific
VDR-knockout mice also develop myocardial hypertrophy,28
in concert with much older data suggesting that vitamin D
exerts direct effects on (or maybe via) the cardiomyocytes.29
Detailed studies in cultured cardiomyocytes showed pro-
found antihypertrophic and antiproliferative actions of
vitamin D metabolites.30–32 Contractility and electrophysiol-
ogy of the heart may be significantly modulated by vitamin D
effects on myocardial calcium handling.33 In this context,
it has been shown that calcium flux, in particular calcium
uptake by cardiomyocytes and calcium sequestration into
the sarcoplasmic reticulum, is modulated by 1,25D.33–36 With
regard to contractility, 1,25D induces an accelerated relaxa-
tion of cardiomyocytes, which may improve diastolic
function of the heart.34 Apart from this, vitamin D meta-
bolites regulate myocardial extracellular matrix turnover by
modulating the expression of matrix metalloproteinases and
tissue inhibitors of metalloproteinases.37,38 Other proposed
vitamin D effects on the myocardium, such as regulation of
energy metabolism or myosin expression, still require further
in-depth studies.33 Finally, the VDR itself was shown to be
regulated by the occurrence of cardiac hypertrophy per se,
suggesting that not only does circulating vitamin D dictate
vitamin D signaling, but also VDR expression may be of
importance.21
VITAMIN D AND RISK FACTORS FOR HEART DISEASE
Accumulating evidence suggests that a poor vitamin D status
may contribute to an increased CV risk profile. A recent
article reports the association between CV risk factors and
vitamin D status in a general health-care population
(440,000 subjects).39 It becomes clear that low 25D levels
strongly correlate with increased prevalence of all classical
CV risk factors.39 We briefly discuss important risk factors
separately.
It is well established that vitamin D deficiency leads to
impaired calcium homeostasis, including secondary hyper-
parathyroidism.1,2 Native and active vitamin D supplementa-
tion reduces elevated parathyroid hormone (PTH) levels.18,19
This may protect against heart diseases when considering the
fact that PTH exerts various deleterious effects on the myo-
cardium and the vessel walls.40 In addition, PTH increases
blood pressure and is associated with mortality and CV
events including sudden cardiac death.40–42
Vitamin D deficiency is not only common among CKD
patients but is also an independent risk factor for the
development of end-stage renal disease.7,43 Vitamin D
metabolites may exert several renoprotective effects such as
suppression of the renin–angiotensin–aldosterone system,
antiproteinuric effects, as well as anti-inflammatory and
immunomodulatory properties with upregulation of regula-
tory T cells (Tregs) that protect against autoimmunity.15,43,44
It is important to note that some studies, including a
randomized controlled trial (RCT) among 281 patients with
diabetic nephropathy, have shown that paricalcitol reduces
albuminuria.15,45
A poor vitamin D status has also been associated with the
prevalence and incidence of arterial hypertension.46 Three
RCT meta-analyses have shown that native vitamin D
supplementation reduces systolic blood pressure by 2 to
6 mm Hg, whereas data on antihypertensive effects of active
vitamin D treatment are still inconclusive.5,47
Furthermore, vitamin D may have a role in the patho-
genesis of type 1 and type 2 diabetes mellitus.2,5,48 Results
from experimental and clinical studies suggest that vitamin D
metabolites exert anti-inflammatory actions, stimulate insulin
secretion, and improve insulin sensitivity, through processes
such as upregulation of the insulin receptor.2,48 This is
partially supported by some small interventional studies, but
whether vitamin D treatment is effective in the prevention
and treatment of diabetes mellitus remains to be proven in
large-scale RCTs.48
Numerous studies evaluated further associations of
vitamin D with other CV risk factors such as certain
inflammatory and coagulation parameters or blood lipids,
but currently available data are insufficient to draw final
conclusions.1–5,49–51 Interestingly, some study results suggest
that statins may increase 25D levels, which in turn may
enhance beneficial effects of statin therapy.4,52,53
Vitamin D may also have a role in the pathogenesis of
vascular diseases because arterial vessel cells are target cells
for vitamin D.54 Effects of antiatherosclerotic vitamin D
include (1) inhibition of macrophage to foam cell formation;
(2) downregulation of vascular smooth muscle cell prolifera-
tion and migration; and (3) suppression of inflammation-
triggered expression of endothelial adhesion molecules.54
Physiological effects of vitamin D may also prevent vascular
calcification by, for example, inhibition of bone morphogenic
protein-2 expression.54–56 This is in line with data on an
inverse association of 25D levels with incident coronary
artery calcification.57 Endothelial dysfunction has also been
linked to a poor vitamin D status in hemodialysis patients.58
VITAMIN D STATUS AND HEART DISEASE
A clinically significant association between vitamin D defici-
ency and heart disease is supported by several case reports of
children with rickets who suffered from cardiomyopathies
but could be successfully cured by vitamin D and calcium
supplementation.33,59 Interestingly, a VDR gene polymorph-
ism was associated with left ventricular mass and predicted
ventricular hypertrophy progression in end-stage renal disease
patients.60 Clinical studies among patients with CKD have
largely shown that a poor vitamin D status is an independent
risk factor for prevalent and incident heart disease, includ-
ing coronary vascular calcification, heart failure, and CV
mortality.8,11–13,55–58 Detailed analyses of specific CV events
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among diabetic hemodialysis patients showed that low 25D
levels were particularly associated with sudden cardiac
death.12 Hence, a poor vitamin D status indicates an
increased CV risk, but it remains to be determined whether
vitamin D deficiency is the cause or the consequence. In this
context, the possibility of reverse causation should be
considered, that is, the fact that heart disease-associated
limitations in sunlight exposure may underlie the association
of vitamin D deficiency and CV risk.
VITAMIN D TREATMENT
Two approaches have been described for vitamin D therapy:
native vitamin D supplementation and active vitamin D
treatment. Clinical data on both therapies are briefly
summarized and discussed below.
Native vitamin D supplementation aims to increase 25D
levels. A meta-analysis of RCTs, largely performed among
frail elderly patients, showed a 7% significant mortality
reduction with native vitamin D supplementation versus
placebo.61 Furthermore, a meta-analysis of randomized trials
showed a nonsignificant trend toward CV disease risk
reduction with vitamin D supplementation (pooled relative
risk, 0.90 (95% confidence interval, 0.77–1.05)).62 There are,
however, no data on the effect of vitamin D supplementa-
tion on CV events or mortality in CKD cohorts. A few
interventional studies among CKD patients showed that
vitamin D intake improves bone and mineral metabolism,
including reductions in PTH levels, decreases inflammatory
parameters, and improves glucose metabolism.18,63–67 It should
also be noted that a study among 158 hemodialysis patients
reported that vitamin D reduces natriuretic peptide levels and
left ventricular mass.66 Another small study among 10 hemo-
dialysis patients showed significant improvements of left
ventricular function after vitamin D therapy.68 In general,
native vitamin D supplementation is relatively easy, cheap,
and safe. According to a rough rule of thumb, a daily intake
of 1000 IU raises 25D levels by B10 ng/ml (25 nmol/l).69
Individual differences should, however, be considered and
25D levels may be determined after at least 3 months of
supplementation.3 Adverse effects, mainly related to hyper-
calcemia, are not observed at daily doses of up to 10,000 IU
vitamin D or at 25D levels up to 150 ng/ml (375 nmol/l).16,70
These data were mainly derived from general populations,
but studies among CKD patients showed similar results on
the safety of vitamin D.18,64–68,70
Currently, none of the large cardiology societies (American
Heart Association, American College of Cardiology, European
Society of Cardiology) include testing of vitamin D status
(or the supplementation of vitamin D) in their respective
guidelines and treatment recommendations for common CV
diseases, such as coronary artery disease and heart failure.
The 2009 Kidney Disease: Improving Global Outcomes
clinical practice guidelines include a rather weak recommen-
dation to test for and treat vitamin D deficiency in patients
with CKD stages 3–5D using treatment strategies recom-
mended for the general population.71 It is further outlined
that it is reasonable to correct vitamin D deficiency in
patients with elevated PTH levels.71 We also believe that
reduced 25D levels in CKD patients should be corrected to
target levels of X30 ng/ml (75 nmol/l) when considering the
multiple health benefits and the safety data of vitamin D.1–6,16
Epidemiological studies suggest that optimal 25D levels for
multiple health outcomes range from 30 ng/ml (75 nmol/l) to
40 ng/ml (100 nmol/l).16 It should also be stressed that native
vitamin D supplementation can slightly increase circulating
1,25D levels.65,72 There are, however, no adequate data on
possible interactions or additive effects of native and active
vitamin D treatment. An intriguing hypothesis is that both
therapies target the same receptor (VDR) but, depending on
tissue-specific differences such as local 1a-hydroxylase
activities, certain cells might be more or less sensitive to
either therapy.
Active vitamin D treatment with 1,25D or other VDR
activators (for example, paricalcitol) is associated with
reduced mortality in CKD patients.72 This therapy is
routinely used to treat secondary hyperparathyroidism and
improves CV risk profile.72 Data on the effect of active
vitamin D treatment on CV events are insufficient, but some
studies evaluated effects on myocardial structure and
function.72–76 In this context, studies among dialysis patients
have largely shown that 1,25D administration improves
parameters of myocardial structure (for example, reduces
myocardial hypertrophy) and left ventricular function.72–76
One study showed reduction of the (corrected) QT interval
and of QT dispersion after calcitriol treatment in hemodia-
lysis patients.76 Paricalcitol has also been shown to reduce
myocardial hypertrophy and was associated with improved
diastolic function in hemodialysis patients.77 Compared with
native vitamin D treatment, active vitamin D therapy has,
however, a relatively narrow therapeutic window with the risk
of hypercalcemia; regular monitoring of mineral metabolism
is therefore required.72
CONCLUSIONS
Vitamin D exerts various effects on the heart, which may be
important for maintenance of normal myocardial structure
and function (Figure 1).33,78 A poor vitamin D status in the
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Figure 1 |Proposed vitamin D effects on the heart. PTH,
parathyroid hormone.
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general population, and in particular among CKD patients, is
associated with an increased risk of heart diseases, including
CV mortality and sudden cardiac death.7–13 Results from
small interventional studies suggest that native and active
vitamin D treatment improve CV risk profiles, as well as
myocardial structure and function. Whether these therapies
are effective in reducing the incidence of heart diseases
remains to be proven in RCT. In line with current guidelines,
we recommend to test for 25D levels and to supplement
native vitamin D in CKD patients (stages 3–5D) with reduced
25D levels.71 In general, we should aim for a sufficient
vitamin D status with 25D levels ofX30 ng/ml.3,16,71 This is a
reasonable approach when considering the multiple health
benefits of vitamin D and the easy, cheap, and safe way of
its supplementation.2,3,16,69,70 Active vitamin D therapy
with 1,25D or its analogs is widely used in end-stage renal
disease patients with secondary hyperparathyroidism, but
this therapy has a relatively narrow therapeutic window
and requires frequent monitoring of mineral metabolism.
Promising data on antiproteinuric and cardioprotective effects
of paricalcitol may, however, extend the future indication
spectrum for active vitamin D treatment.19,41,45,79–81
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